Regeneron Pharmaceuticals REGN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 102.2%-10.8pp | 105.1%-10.1pp | 108.2%-9.7pp | 111%-10.4pp | 112.9%-13.7pp | |
| Net margin | 124.6%-4.1pp | 126.8%+0.7pp | 126.5%+1.3pp | 128%+5.9pp | 128.7%+4.7pp | |
| Returns | ||||||
| Return on equity | 59.9%-5.7pp | 61.4%-3.6pp | 62.4%-2.8pp | 64.4%-0.9pp | 65.6%-2.4pp | |
| Return on invested capital | 43%-9.6pp | 45%-10.1pp | 48%-9.6pp | 50.7%-10.2pp | 52.6%-12.2pp | |
| Efficiency | ||||||
| Asset turnover | 1.5×-0.1× | 1.5×-0.1× | 1.5×-0.1× | 1.6×-0.1× | 1.6×-0.1× | |
| Liquidity | ||||||
| Current ratio | 16.4×-4.0× | 17.7×-3.0× | 18.3×-3.4× | 19.5×-2.0× | 20.4×-1.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Net debt / EBITDA | 0.1×-0.2× | 0.1×-0.4× | 0.2×-0.2× | 0.3×0.0× | 0.3×0.0× | |
| Per Share | ||||||
| Book value per share | $1,144.05+12.6% | $1,116.56+13.2% | $1,083.77+12.9% | $1,047.36+13.0% | $1,016.10+13.7% | |
| Valuation | ||||||
| Market capitalization | $278.79B-25.6% | $266.44B-34.9% | $263.6B-37.9% | $317.64B-20.2% | $374.55B+3.7% | |
| Price / earnings | 62.1×-21.6× | 59.1×-36.2× | 58.8×-42.4× | 70.2×-28.5× | 83.8×-6.5× | |
| Price / sales | 19.3×-7.8× | 18.7×-11.3× | 18.6×-13.1× | 22.6×-7.5× | 27×-0.7× | |
| Price / book | 9×-3.9× | 8.8×-5.6× | 8.8×-6.5× | 10.8×-4.2× | 12.9×-1.2× | |
| EV / EBITDA | 66.5×-19.0× | 62.9×-30.8× | 60.8×-36.3× | 72.4×-18.0× | 85.4×+4.9× | |
| Dividend yield | 1.7%+1.6pp | 1.4%— | 0.9%— | 0.5%— | 0.1%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regeneron Pharmaceuticals's profit margins?
- Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.
- Where do Regeneron Pharmaceuticals's ratios come from?
- Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
